BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sitneprotafib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sitneprotafib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05288205-2238@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sitneprotafib: Phase 1/2 readout est. (NCT05288205)
DESCRIPTION:Sitneprotafib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Sol
 id Tumors Harboring KRAS p.G12C Mutation\nEstimated primary completion: Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sitneprotaf
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5288205
URL:https://assetmemo.bio/drug/sitneprotafib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06416410-2238@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sitneprotafib: Phase 3 readout est. (NCT06416410)
DESCRIPTION:Sitneprotafib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: J
 AB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatme
 nt of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation\nEstim
 ated primary completion: 30 September 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/sitneprotafib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06416410
URL:https://assetmemo.bio/drug/sitneprotafib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
